নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

wyeth (nz) ltd - conjugated estrogens 0.625mg (15mg dessication with lactose,includes 3% overage);  ; medroxyprogesterone acetate 5mg (5.2mg includes 4% overage);  ; conjugated estrogens 0.625mg - tablet - active: conjugated estrogens 0.625mg (15mg dessication with lactose,includes 3% overage)   medroxyprogesterone acetate 5mg (5.2mg includes 4% overage)   excipient: calcium sulfate carnauba wax glyceryl mono-oleate indigo carmine lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose   opacode black s-8-27741 povidone shellac stearic acid sucrose     titanium dioxide   active: conjugated estrogens 0.625mg excipient: calcium sulfate carnauba wax glyceryl mono-oleate ink lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose shellac stearic acid sucrose titanium dioxide urethane dimethacrylate luting resin

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

wyeth (nz) ltd - conjugated estrogens 0.625mg;  ; norgestrel 0.15mg - tablet - 0.62 mg - active: conjugated estrogens 0.625mg   excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opaglos clear 98z19173 shellac stearic acid sucrose titanium dioxide urethane dimethacrylate luting resin active: norgestrel 0.15mg excipient: calcium carbonate carnauba wax iron oxide red lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose titanium dioxide white beeswax

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

wyeth (nz) ltd - conjugated estrogens 1.25mg;  ; norgestrel 0.15mg - tablet - 1.25 mg - active: conjugated estrogens 1.25mg   excipient: calcium sulfate carnauba wax glyceryl mono-oleate ink lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose quinoline yellow shellac stearic acid sucrose sunset yellow fcf titanium dioxide active: norgestrel 0.15mg excipient: calcium carbonate carnauba wax iron oxide red lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose titanium dioxide white beeswax

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

wyeth (nz) ltd - guanabenz acetate - tablet - 4mg, 8mg, 16mg - active: guanabenz acetate

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

physicians total care, inc. - desvenlafaxine succinate (unii: zb22enf0xr) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - pristiq, a selective serotonin and norepinephrine reuptake inhibitor (snri), is indicated for the treatment of major depressive disorder (mdd) [see clinical studies ( 14 ) and dosage and administration ( 2.1 ) ]. the efficacy of pristiq has been established in four 8-week, placebo-controlled studies of outpatients who met dsm-iv criteria for major depressive disorder. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in th

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - desvenlafaxine succinate (unii: zb22enf0xr) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14) ] . there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for antidepressants at 1-844-405-6185. there are no published studies on desvenlafaxine extended-release tablets in pregnant women; however published epidemiologic studies of pregnant women exposed to venlafaxine, the parent compound, have not reported a clear association with adverse developmental outcomes (see data) . there are risks associated with untreated depression in pregnancy and with exposure to snris and ssris, including desvenlafaxine extended-release tablets, during pregnancy (see clinical considerations). in reproductive developmental studies in rats and rabbits treated with desvenlafaxine succinate, there was no evidence of

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

macoven pharmaceuticals - desvenlafaxine (unii: ng99554anw) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . - hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation.  angioedema has been reported in patients treated with desvenlafaxine [see adverse reactions (6.1)] . - the use of maois intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets is contraindicated because of an increased risk of serotonin syndrome. the use of desvenlafaxine extended-release tablets within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration  (2.8)   and  warnings and precautions  (5.2)]. -   starting desvenlafaxine extended-release tablets in a patient who is being treated with maois such as linezolid or intraveno

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

u.s. pharmaceuticals - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), bazedoxifene acetate (unii: j70472ud3d) (bazedoxifene - unii:q16tt9c5bk) - estrogens, conjugated 0.45 mg - duavee is indicated in women with a uterus for: - use duavee for the shortest duration consistent with treatment goals and risks for the individual woman. postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary. - when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered. duavee is contraindicated in women with any of the following conditions: - undiagnosed abnormal uterine bleeding - known, suspected, or past history of breast cancer - known or suspected estrogen-dependent neoplasia - active deep venous thrombosis, pulmonary embolism, or history of these conditions - active arterial thromboembolic disease (for example, stroke, myocardial infarction) or history of these conditions - hypersensitivity (for example, anaphylaxis, angioedema) to estrogens, bazedoxifene, or any ingredients -

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

amneal pharmaceuticals of new york, llc - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone 0.4 mg - norethindrone and ethinyl estradiol tablets, chewable and ferrous fumarate tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and implants, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. 1 among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason 2 among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first yea

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - oestradiol -